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Abstract: Background Coronavirus disease 19 (COVID-19), is an infectious disease caused by the Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This virus is causing a pandemic with more
than 40 million proven infections worldwide. Aim In order to summarize the clinical characteristics of
coronavirus disease-19 (COVID-19) in solid organ transplant (SOT) recipients, we conducted a systematic
review of studies on COVID-19 in these patients. Methods The literature search was conducted repeatedly
between March 16th and May 1st, 2020. We searched original papers, observational studies, case reports,
and meta-analyses published between December 2019 and May 1st 2020 using two databases (PubMed,
Google Scholar) with the search terms: [transplant OR immune suppression] AND [COVID-19 OR SARS-
CoV-2]. Further inclusion criteria were publications in English, French, German and Italian and reference
to humans. We also searched the reference lists of the studies encountered. Studies on non-solid organ
transplantation were excluded, as well as animal and in vitro studies. Results From an initial search 37
potential articles were retrieved, of which 15 were excluded after full-text screening (not being case reports
or case series), leaving 22 studies for inclusion. No further studies were identified from the bibliographies
of the retrieved articles. Conclusion Between March 16th and May 1st, 2020, only 49 SOT recipients
have been described in literature. Most of these patients survived, and had a fairly mild disease course.
Based on the limited research data, no firm conclusions can be made concerning specific treatment of
SOT recipients, but the current evidence suggests that immunosuppression, especially the calcineurin
inhibitors, decreases the incidence and improves the outcome of symptomatic COVID-19, by preventing
hyperinflammation (cytokine storm). Evidence based guidelines are urgently needed for this particular
group of patients.
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Introduction
Community-acquired respiratory viruses (CARVs) cause 
upper and/or lower respiratory tract disease after solid organ 
transplant (SOT) and are related to high morbidity and mor-
tality in SOT recipients. The most frequent CARVs are human 
parainfluenza virus (PIV), metapneumovirus (MPV), rhino-/
enterovirus (REV), respiratory syncytial virus (RSV), influenza 
virus (IV) and coronaviruses (CoVs). To date, 7 human CoVs 
have been identified. The 4 CoV species with a fairly benign 
outcome are called 229E, OC43, NL63 and HKU1 and in immu-
nocompetent people generally cause mild respiratory or gas-
trointestinal symptoms. The 3 highly dangerous CoV species, 
associated with outbreaks with a high morbidity and mortal-
ity, are the Severe Acute Respiratory Syndrome Coronavirus 
(SARS-CoV), the Middle East Respiratory Syndrome Corona-
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Abstract
Background: Coronavirus disease 19 (COVID-19), is an infectious disease caused by the Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2). This virus is causing a pandemic with more than 40 million proven infections 
worldwide. 
Aim: In order to summarize the clinical characteristics of coronavirus disease-19 (COVID-19) in solid organ transplant 
(SOT) recipients, we conducted a systematic review of studies on COVID-19 in these patients.
Methods: The literature search was conducted repeatedly between March 16th and May 1st, 2020. We searched 
original papers, observational studies, case reports, and meta-analyses published between December 2019 and May 
1st 2020 using two databases (PubMed, Google Scholar) with the search terms: [transplant OR immune suppression] 
AND [COVID-19 OR SARS-CoV-2]. Further inclusion criteria were publications in English, French, German and Italian 
and reference to humans. We also searched the reference lists of the studies encountered. Studies on non-solid organ 
transplantation were excluded, as well as animal and in vitro studies. 
Results: From an initial search 37 potential articles were retrieved, of which 15 were excluded after full-text screening 
(not being case reports or case series), leaving 22 studies for inclusion. No further studies were identified from the 
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virus (MERS-CoV) and the recent coronavirus SARS-CoV-2.
The disease caused by infection with SARS-CoV-2 is called 
COVID-19. 
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The aim of this review is to summarize the clinical charac-
teristics in SOT recipients, as has been reported in the med-
ical literature. Among these clinical characteristics, we sum-
marized the type of organ transplantation (heart, lung, liver, 
kidney), age, sex, type of immunosuppressive therapy, symp-
toms at presentation, temperature, oxygen saturation (SpO
2
), 
C-reactive protein (CRP) level, chest computed tomography 
(CT), severity of COVID-19 (Siddiqi stage), treatment and out-
come. These findings are presented in a table.
Methods
The literature search was conducted repeatedly between 
March 16th and May 1st, 2020. We searched original papers, 
observational studies, case reports, and meta-analyses pub-
lished between 2019 and 2020 using two databases (PubMed, 
Google Scholar) with the search terms: [transplant OR immu-
nosuppression] AND [COVID-19 OR SARS-CoV-2]. Further in-
clusion criteria were publications in English, French, German 
and Italian and reference to humans. We also searched the 
reference lists of the studies encountered. Exclusion criteria 
were non-solid organ transplantation, animal and in vitro 
studies. Reviews were excluded as well. A panel of two clini-
cians (two pulmonary physicians, R.H. and M.M.S.) conducted 
the literature search, and three clinicians (pulmonary physi-
cians, R.H., C.S. and M.M.S.) reached consensus on the arti-
cles that were included in this review, based on the previously 
described in- and exclusion criteria.
Results
From an initial search 37 potential articles were retrieved, 
of which 15 were excluded after full-text screening (not being 
case reports or case series), leaving 22 studies for inclusion 
(Table 1). No further studies were identified from the bibli-
ographies of retrieved articles. The results of the studies are 
summarized in Table 1. There were three studies describing 
patients with a heart transplantation (including 3 patients), 
one study with a combined heart and kidney transplantation 
(1 patient), 12 with a kidney transplantation (35 patients), 
5 with a liver transplantation (5 patients) and 4 with a lung 
transplantation (5 patients).
The distribution of age, sex and the immunosuppressive 
therapy are shown in Table 1. Symptoms at presentation in-
cluded constitutional (fatigue, fever, chills, confusion), respi-
ratory (cough, chest tightness, dyspnea) and gastrointestinal 
symptoms (diarrhea, nausea, vomiting, severe abdominal 
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Abbreviations: ATG = antithymocyte globulin (thymoglobulin); Aza = azathioprine; bela = belatacept; bilat. = bilateral; CRP = C-reactive 
protein; CT chest = computed tomography of the chest; CXR = chest X-ray; CyA = cyclosporin A; ECMO = extracorporeal membrane 
oxygenation; everol = everolimus; GGO = ground-glass opacity; HFOT = high flow oxygen therapy; HCQ = hydroxochloroquine; inh. = 
inhalation; IST = immunosuppressive therapy; iv = intravenous; IVIG = intravenous immunoglobulin G; leflu = leflunomide; Mes = mesalamine; 
MMF = mycophenolate mofetil; MTP = methylprednisolone; MV = mechanical ventilation; NIV = non-invasive ventilation; po = per os; Pred 
= Prednisone; Ptx = pneumothorax; PE = pleural effusion; rh-IFN α = recombinant human interferon alpha; rh-GCSF = recombinant human 
granulocyte colony-stimulating factor; Tac = tacrolimus, unilat. = unilateral
the infection, developed a stage III COVID-19 disease (see de-
tails in Table 1).
Discussion
During the current SARS-CoV-2 pandemic, affecting tens 
of millions of individuals worldwide, only a limited number of 
SOT recipients have been reported in case reports and case 
series. Between March 16th and May 1st, 2020, only 49 SOT 
recipients have been described in literature. Most of these 
patients survived, and had a fairly mild disease course. It may 
seem surprising, that the life-threatening, highly contagious 
SARS-CoV-2, did not affect the large majority of the SOT pa-
tients, who are on chronic immunosuppression. Compared 
to the millions of people with COVID-19 worldwide, data on 
COVID-19 patients with SOT are relatively scarce. Even in the 
heavily infected Lombardy region (Italy), only three of 111 
long-term liver transplant survivors died within 3-12 days 
following severe COVID-19 [2]. All of these were male, older 
than 65-years, receiving antihypertensive drugs, overweight 
(BMI > 28 kg/m2), with hyperlipidemia, and diabetes [2]. Two 
of these patients were on cyclosporine treatment, the oth-
er one on tacrolimus. By contrast, in this Italian liver trans-
plantation center, 3 of the 40 recently transplanted patients 
were tested SARS-CoV-2 positive and were experiencing an 
uneventful course of disease [2]. This is in sharp contrast with 
the many ascertained SARS-CoV-2 infections in the general 
population of the Lombardy region, with 7199 virus-related 
deaths as of March 31, 2020 [3].
Even more surprising is the fact that SOT recipients, in 
whom a high prevalence of posttransplant comorbidities due 
to immunosuppression is known, are relatively underrepre-
sented in COVID-19 patient cohorts. One of the COVID-19 risk 
factors is diabetes mellitus, which is prevalent in 20-40% of 
SOT recipients [4].
pain). Muscle aches and rhinorrhea have also been report-
ed. Most, but not all, patients had fever. Oxygen saturation 
and the level of the CRP have not been reported in all studies 
(Table 1). In most patients’ chest CT showed bilateral ground-
glass opacities (GGO) (Table 1). Severity staging was made 
according to Siddiqi [1]. Stage I represented mild, early SARS-
CoV-2 infection, without pulmonary involvement or hypoxia. 
In stage II (moderate) there is pulmonary involvement with-
out (IIa) and with (IIb) hypoxia. These patients generally are 
hospitalized. Stage III is the severe stage with systemic hy-
perinflammation (cytokine storm), including systemic organ 
involvement with shock, vasoplegia, respiratory failure and 
cardiopulmonary collapse. The different treatments and pa-
tient outcome are summarized in Table 1. All but 5 patients 
survived.
The two patients who underwent heart transplantation 
survived. They were both on tacrolimus and mycophenolate 
mofetil (MMF) maintenance immunosuppression, in one of 
them tacrolimus and MMF were discontinued after the di-
agnosis of COVID-19. One patient underwent both a heart- 
and kidney transplantation, and continued tacrolimus but 
discontinued MMF, while prednisolone was continued un-
changed. He also survived the SARS-CoV-2 infection. There 
are 34 patients (9 case reports and 2 case series) on patients 
with COVID-19 after renal transplantation, most of them con-
tinued tacrolimus. Three patients did not survive COVID-19. 
Three patients with a liver transplantation, one of them was 
a 6-months-old girl, another was a 59-year-old patient, who 
died after a hospitalization of 45 days. For the two adult pa-
tients immunosuppression was reduced by lowering the tac-
rolimus doses. Four patients with a lung transplantation de-
veloped COVID-19, one died and in one patient a definitive 
outcome has not been reported yet. Three of them were on 
tacrolimus therapy, and this treatment remained unchanged 
after the COVID-19 diagnosis. The patient who did not survive 
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patients can present with atypical symptoms, therefore the 
COVID-19 diagnosis may not be considered, especially when 
symptoms are both mild and atypical [9]. This observation 
could be important for the detection of COVID-19 in SOT 
recipients since at the early phase of the pandemic in many 
centers only symptomatic patients were tested, and there-
fore probably the number of SARS-CoV-2 infections has been 
underestimated.
Another explanation may be the prudent behavior of the 
SOT patients, including minimizing social contacts, personal 
hygiene, etc. This has also been observed in the Italian cystic 
fibrosis (CF-) population [10], in which ten patients with cystic 
fibrosis out of 42161 people in the region known to be infect-
ed with SARS-CoV-2, all were infected by family members. Al-
though a comparable situation has also been observed in CF 
patients in other European countries, other factors, such as 
long-term use of prophylactic or immunomodulatory antibi-
otics, might be a protective factor and lead to reduced symp-
toms despite infection [10].
Nevertheless, a certain case-fatality bias cannot be ex-
cluded, as only symptomatic patients were tested, due to 
scarcity of both test material and health care personnel in the 
acute phase of the COVID-19 pandemic, with an overwhelm-
ing number of patients presenting in a short period of time. 
Further studies need to clarify the above-mentioned hypoth-
eses.
Clinical manifestations of SARS-CoV-2 infection 
in SOT patients
In COVID-19, the classical triade is fever, fatigue and dry 
cough, which were also the most common clinical features 
of the COVID-19 patients in Wuhan (China). However, the 
immunocompromised status of SOT recipients can be asso-
ciated with more atypical symptoms with gastrointestinal 
complaints and can be easily overlooked and not recognized 
as symptomatic COVID-19. In a study with 1141 immunocom-
petent adults, 183 patients (16%) presented with gastroin-
testinal symptoms, the most common symptom was loss of 
appetite, followed by nausea and vomiting [11]. Diarrhea and 
abdominal pain were the presenting symptom in 37% and 
25% of patients, respectively, in another study [12]. When 
infecting human cells, SARS-CoV-2 uses the human cells ex-
pressing angiotensin converting enzyme 2 (ACE2) as an entry 
receptor. The cells expressing ACE2 are not only expressed in 
the upper and lower airways, but also in the gastro-intesti-
nal tract, and as such can infect the ACE2 expressing entero-
cytes. However, the mechanism and presentation of gastro-
intestinal symptoms in immunocompetent in comparison to 
immunosuppressed (SOT) patients could be different. Along 
with the known routes of transmission, alternative routes of 
transmission are suspected. Interestingly, there is increasing 
evidence showing that coronaviruses gain access to the CNS 
via a synapse-connected route, whereas a hematogenous or 
lymphatic route is very unlikely [13]. By entering the CNS, also 
the medullary cardiorespiratory center from the mechanore-
ceptors and chemoreceptors in the lung and the lower air-
ways can be reached, contributing to the respiratory failure 
by a neurological mechanism.Acute presentations of the neu-
Incidence of viral infections in SOT patients
Although the above mentioned CoV species 229E, OC43, 
NL63 and HKU1 generally are not associated with severe dis-
ease, this is not the case for immunosuppressed patients. In 
lung transplant recipients, survival after lung transplantation 
is not yet as good as that after other solid organ transplants. 
In these patients, 5 years post transplantation, chronic lung 
allograft dysfunction (CLAD) develops in about 50% and has 
a major impact on post-transplant survival [3]. One study in-
cluding 98 patients who underwent a lung transplantation, 
showed that the CoV species were the second largest group 
of CARVs (19.2%) in the first year after lung transplantation. 
Besides, this study showed that CoV in particular was associ-
ated with increased risk for CLAD development [5].
In other respiratory viral infections, such as influenza, SOT 
patients experience prolonged clinical disease, with the risk 
of progression of the infection to the lower respiratory tract 
and increased mortality when compared to the immunocom-
petent population [6]. A multicenter cohort study, with 559 
patients, of which 56 were immunosuppressed (including 
18 SOT recipients) were prospectively characterized, study-
ing the clinical manifestations and outcomes of confirmed-
influenza A 2009 (H1N1) virus infection. Although clinical 
symptoms at diagnosis were similar in both groups, immu-
nosuppressed patients with pandemic influenza had bacteri-
al co-infections more frequently (17.9% vs. 6.4%, p = 0.02), 
specifically Gram-negative bacilli and Staphylococcus aureus 
infections. Mortality was higher in immunosuppressed pa-
tients (7.1% vs. 1.8%, p < 0.05) [6]. Another study of hospi-
talized immunosuppressed patients with seasonal influenza 
reported that one-half of the patients had a pneumonia and 
one-third of patients were admitted to the ICU, with a 10% 
mortality rate [7].
Based on the preliminary data available for COVID-19 in 
SOT there seems to be a decreased morbidity and mortality 
in case of infection with SARS-CoV-2.
One explanation may be the potential protective effect of 
the immune suppression in SOT patients. As has been men-
tioned above, in the clinical manifestations of COVID-19 three 
stages of severity (according to Siddiqi) can be seen [1]. In the 
first stage, early in COVID-19, there is a high viral load with 
only mild constitutional symptoms. In the second stage, the 
viral load decreases, but there is an increasing host inflam-
matory response. This leads to dyspnea with moderate to se-
vere hypoxia, with low or normal procalcitonin. Stage III is the 
hyperinflammation phase, in which most patients no longer 
have detectable virus but show an extreme host inflammato-
ry response, leading to acute respiratory distress syndrome 
(ARDS), systemic inflammatory response syndrome (SIRS)/
shock, cardiac failure and elevated inflammatory markers. In 
this stage, the immune system is overreacting with an over-
shooting inflammatory response, also called a cytokine storm. 
In SOT patients, stage III is extremely rare. A protective effect 
of immunosuppressive drugs, especially by the calcineurin 
inhibitors, might play a role in preventing this stage, as was 
observed in SARS-CoV-1 infections [8].
Secondly, as has been illustrated by Steinack, et al., SOT 
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were not many alternatives, remdesivir has been given to 
many COVID-19 patients. Moreover, a confounding factor 
might be that in nearly 20% of patients in this trial, remde-
sivir was combined with lopinavir/ritonavir. Any effects influ-
encing clinical improvement or mortality of this combination 
cannot be fully excluded. Remdesivir's metabolism is likely 
mediated by hydrolase activity, and although it is a substrate 
for cytochrome P450 (cyp) 3A4 in vitro, a clinically important 
CYP3A4 inhibition is not to be expected [19].
Chloroquine/hydroxychloroquine: In the early phase of 
the COVID-19 pandemic, chloroquine (CQ) and hydroxychlo-
roquine (HCQ) have been proposed as treatment or preven-
tion of COVID-19, since in vitro data show inhibition of the 
SARS-CoV-2 by increasing the pH of intracellular lysosomes 
and endosomes, hampering the fusion of the viral mem-
brane. In addition, (H)CQ has been shown to alter the glyco-
sylation of ACE2, which is used by the virus to infect the host 
cells. Both CQ and HCQ block the transport and subsequent 
release of the viral genome [20]. CQ and HCQ are converted 
to active metabolites by cytochrome P450 enzymes including 
CYP3A4 [19]. It is noteworthy that CQ and HCQ are associat-
ed with QTc prolongation, which can be an added risk in SOT 
patients since CNIs (tacrolimus and cyclosporin) and mTOR 
inhibitors can also prolong the QT-interval. Moreover, these 
patients frequently are on maintenance therapy with macro-
lides such as azithromycin and sometimes antifungals such as 
itraconazole. The concurrent use of two or three drugs that 
cause QT interval prolongation may result in additive effects 
and increase the risk of ventricular arrhythmias including Tor-
sade de Pointes and even sudden death [21]. In patients on 
CNIs and mammalian target of rapamycin inhibitors (mTORi), 
receiving therapy with CQ or HCQ, at least electrocardiogra-
phy before and during therapy should be performed. Ideally 
continuous cardiac monitoring should be performed especial-
ly when multiple QT interval prolonging drugs are involved 
that cannot be paused or stopped. Therefore, CQ and HCQ 
should be prescribed with great caution and close monitoring 
of blood concentrations of the immunosuppressive therapy 
should be performed. Patients reporting symptoms like diz-
ziness, lightheadedness, palpitation, irregular heart rhythm, 
shortness of breath or syncope should receive urgent med-
ical attention, to exclude cardiac arrhythmia. Many of these 
symptoms could be falsely attributed to COVID-19 itself in-
stead of considering them potential cardiac adverse events 
of the introduced medication. One should bear in mind that 
both CQ and HCQ have long elimination half-lives of approxi-
mately 40-60 days.
However, having initially been a controversial an-
ti-COVID-19 treatment, several studies now have shown that 
treatment of COVID-19 with CQ or HCQ is without benefit 
[22,23].
As many patients, including SOT recipients, have received 
this treatment, we have mentioned (H)CQ in this review.
Lopinavir/ritonavir: One of the main antiviral drugs used 
in the initial phase of the pandemic to treat COVID-19 is the 
antiretroviral HIV dual protease inhibitor lopinavir-ritonavir. 
Ritonavir increases the plasma half-life of lopinavir via inhi-
roinvasive effects of SARS-CoV-2 include headache, nausea 
and vomiting. In SARS, the SARS-CoV has been demonstrated 
in the brains from both patients and experimental animals, 
where the brainstem was heavily infected [13,14].
Another finding in most of the case reports and case se-
ries with COVID-19 patients in SOT recipients, is the milder 
('early infection', stage I) or moderate ("pulmonary phase", 
stage II) stage of disease observed, whereas severe COVID-19 
("hyperinflammation" or "cytokine storm", stage III) was ex-
tremely rarely described [1]. This was even observed in pa-
tients with significant lymphopenia, elevated inflammatory 
markers (CRP, IL-6), LDH, D-dimer and troponin I, all of which 
were associated with increased disease severity and poorer 
outcomes in prior COVID-19 studies of mainly immunocom-
petent patients [15].
One or more pathophysiological responses to SARS-CoV-2 
and COVID-19 could be altered by immunosuppression in SOT 
patients, although the exact mechanism of this disease modi-
fying phenomenon and its typical presentation, incidence and 
severity urgently needs to be investigated in further studies. 
One study reported more severe outcomes (18% mortality, 
n = 16/90) in SOT recipients (of whom 47 were kidney recip-
ients, 17 lung, 13 liver, 9 heart and 5 dual-organ recipients), 
but this could probably be attributed to limited testing, lead-
ing to non-detection of mild and asymptomatic cases [16].
Current "standard" treatment of COVID-19, pos-
sible candidate compounds and interaction po-
tential in SOT recipients?
In the absence of a generally accepted effective pharma-
cological treatment for COVID-19, many existing treatments 
are currently being investigated. Until now, the optimal med-
ical management (both in the immunocompetent as in the 
immune suppressed patients) is unknown. Some pharmaco-
logical interventions have shown promising effects in certain 
patients, but no single medication or medication combination 
has emerged as standard of care yet.
Remdesivir: This drug was used in the Ebola outbreak, 
and also showed activity against SARS-CoV-1 and MERS-CoV. 
It had shown effectiveness against SARS-CoV-2 in animal and 
in vitro studies. Wang et al. published the first randomized, 
double-blind, placebo-controlled trial of remdesivir for treat-
ing severe COVID-19 [17]. In this study, in which 158 patients 
admitted to the hospital for severe COVID-19 received rem-
desivir and 79 placebo, remdesivir was not associated with 
statistically significant clinical benefits [17]. The hazard of 
28-day clinical improvement for 158 patients with remdesivir 
was only 1.2 times (95% CI 0.9 to 1.8) the hazard of place-
bo treatment and the 28-day mortality in both these groups 
did not differ. Glaus et al. suggested that these disappoint-
ing findings could be explained by the fact that remdesivir 
inhibits the coronavirus early in the life cycle according to in 
vitro and animal studies, and remdesivir might thus require 
initiation before the peak viral replication [18]. Also Wang et 
al. reported a stronger clinical effect when remdesivir treat-
ment was started within 10 days of symptom onset compared 
to those who started after this time [17]. However, as there 
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Besides being effective against the virus or its disease 
manifestations, the medication used to treat COVID-19 in 
SOT recipients needs to be evaluated for interactions with 
preexisting drugs in these polymedicated patients. The drugs 
that merit attention in this context are mentioned in Table 2. 
This topic can be even more complex when the SOT patients 
with COVID-19 are in the ICU setting because organ dysfunc-
tion, lower serum albumin, high volume of distribution and a 
strong inflammation need to be taken into account. They are 
frequently dependent on vasopressors. All these factors can 
change the distribution, metabolism and pharmacokinetics of 
the therapeutic antiviral drugs and/or the immunosuppres-
sive drugs, having a narrow therapeutic index.
The CYP3A enzyme system is responsible for the metabo-
lism of many drugs, including the immunosuppressive drugs, 
especially the CNI and mTORi. Certain drug substrates inhib-
it isoforms of the cytochrome P450 enzyme activity, such 
as many of the drugs used experimentally for COVID-19 are 
known as strong CYP3A4 inhibitors. 
As a substrate for the CYP3A system, tacrolimus levels 
may increase dramatically with concurrent protease inhibitor 
treatment. Moreover, tacrolimus can also inhibit the meta-
bolic action of the CYP3A system, thereby even further in-
creasing the levels of protease inhibitors. Dose reductions of > 
90% can be indicated, with a usual requirement of tacrolimus 
of 0.5-1 mg/week to maintain therapeutic tacrolimus blood 
concentrations when lopinavir/ritonavir is used [21,27]. As a 
potent immunosuppressive drug with a narrow therapeutic 
window, increased tacrolimus levels lead to toxicity as well 
as immunosuppression-related infections. A problematic 
drug-drug interaction in a kidney transplant recipient with 
COVID-19 has been reported with tacrolimus 5 mg b.i.d. com-
bined with lopinavir/ritonavir (and due to diarrhea replaced 
with darunavir/cobicistat), leading to neuropsychiatric symp-
toms and a tacrolimus level of 90.5 ng/mL on the fourth day 
of treatment [28].
bition of CYP3A metabolism, and is a strong CYP3A4 inhibi-
tor, increasing serum levels of CYP3A4 substrates. This drug 
showed activity against SARS-CoV, when added to ribavirin 
and steroids. However, in patients with SARS-CoV-2 infec-
tions in the early phase of the pandemic, the effectiveness 
of this combination could not be demonstrated in a study of 
199 hospitalized patients with severe COVID-19, showing no 
improvement above standard care [24].
Ribavirin: In patients with SOT ribavirin has been used to 
treat infections with RSV, PIV and MPV, and has also been 
used in high doses in combination with corticosteroids or 
interferon to treat for SARS-CoV and MERS-CoV. In patients 
with SARS-CoV-2 it has been administered intrials as mono-
therapy or in combination with other drugs. It has the advan-
tage of having a broad antiviral activity, being widely avail-
able and creating relatively low costs. Currently ribavirin has 
not a prominent place in most treatment protocols, and a 
recent larger retrospective study did not show an improved 
viral clearance for SARS-CoV-2, and also did not improve the 
mortality rate in COVID-19 [25]. It is noteworthy that ribavirin 
may lead to toxicity problems due to drug interaction when 
COVID-19 patients with SOT develop secondary mycotic in-
fections and are treated with amphotericin B.
Tocilizumab: Tocilizumab is a monoclonal antibody direct-
ed toward the IL-6 receptor, which licensed for the treatment 
of rheumatoid arthritis in adults and may be also a potential 
therapy to treat patients with the severe COVID-19 stage III 
disease. These patients are characterized by hyperinflam-
mation, in which interleukin (IL-)6 appears to play an im-
portant role: IL-6 concentrations are elevated in this stage of 
COVID-19. High levels of IL-6 can suppress CYP enzyme func-
tions, so that a treatment with tocilizumab, if effective, may 
lead to a better CYP enzyme activity, thus potentially affecting 
all drugs with CYP metabolism [21,26].
COVID-19 treatments and interactions with the 
immunosuppressive therapy
Table 2: Important drug-drug interactions of COVID-19 treatments with immunosuppressive drugs. (H)CQ = (hydroxy)chloroquine; QTc = 
corrected QT-interval.
Remdesivir (H)CQ Lopinavir/ritonavir Ribavirin Tocilizumab
Tacrolimus no interaction 
expected
QTc prolongation neuropsychiatric effects in 
tacrolimus intoxication reduce 
tacrolimus to 0.5-1.0 mg/week
no interaction 
expected
unchanged, or increase 
tacrolimus with close 
monitoring








unchanged, or increase 
cyclosporin with close 
monitoring
Sirolimus no interaction 
expected
QTc prolongation reduce sirolimus,
close monitoring, strong drug-
drug interaction expected with 
high sirolimus levels 
no interaction 
expected
unchanged, or increase 
sirolimus with close 
monitoring
Mycophenolate generally, discontinue or decrease dosage with close monitoring MMF concentrations
Prednisolone generally, continue or increase if other immunosuppressive drugs are discontinued, no routine monitoring of drug 
concentrations
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shedding, which had been reported in patients with MERS 
[39,40]. Corticosteroid treatment initially was not supported 
by clinical evidence in the treatment of ARDS in COVID-19 al-
though data from SOT recipients are missing and the main-
tenance or slightly increased dose of corticosteroid (adrenal 
insufficiency, stress dose) should be given.
However, as we know now, in severe COVID-19 (Siddiqi 
phase III), autopsies not only showed the Diffuse Alveolar 
Damage (DAD) in clinically ARDS patients, but also compo-
nents with organizing pneumonia (OP) or non-specific inter-
stitial pneumonia (NSIP), which are potentially corticosteroid 
responsive. Beside the irreversible post-COVID-19 fibrosis 
(DAD, clinically ARDS) there could be also a reversible, more 
inflammatory, component (OP, NSIP) that could improve on 
corticosteroid treatment. However, there is no international 
consensus on this topic yet. Importantly, before starting corti-
costeroids in SOT recipients, invasive pulmonary aspergillosis 
(IPA) should be excluded [41]. Although IPA is a contraindi-
cation for corticosteroid treatment, this does not hold true 
for the COVID-19-associated pulmonary Aspergillosis (CAPA) 
[42]. In case of CAPA, being a relative but not absolute con-
traindication for corticosteroid treatment, it is mandatory 
to treat Aspergillus as soon as corticosteroids are initiated. 
Beside Aspergillus treatment, bronchoalveolar lavage should 
exclude positive herpes simplex (HSV) and cytomegalovirus 
(CMV) infection by PCR. In case of positive HSV and CMV in the 
lower airways, viral load should be followed-up, and therapy 
with aciclovir/ganciclovir should be considered. Currently, in 
most transplant centers, dexamethason is the corticosteroid 
treatment of choice based on the RECOVERY trial results [43]. 
In the prospective meta-analysis of September 2020, Sterne, 
et al. included 7 randomized controlled trials with a total of 
1703 included patients, including hospitalized and critically 
ill COVID-19 patients [44]. In these patients, they compared 
the effect of corticosteroids to standard care or placebo. 
There were 222 deaths among the 678 patients randomized 
to corticosteroids, and 425 deaths among the 1025 patients 
randomized to usual care or placebo. It was concluded that 
systemic corticosteroids compared with usual care or place-
bo, was associated with lower 28-day all-cause mortality [44]. 
Sirolimus is an inhibitor of the IL-2 receptor, preventing 
proliferation of T-lymphocytes, and reducing the production 
of antibodies. It is an alternative to tacrolimus or CsA, for ex-
ample in patients who develop a decreased renal function 
on CNI treatment. Although the interaction with lopinavir/
ritonavir can lead to very high levels of sirolimus and thus re-
quires close monitoring, it could also have an antiviral effect 
that may be beneficial [45]. In MERS-CoV, it showed improve-
ment of the infection in over 60% of patients. Also, in patients 
with a severe H1N1 pneumonia with acute respiratory fail-
ure sirolimus improved the prognosis significantly [32]. In vi-
tro studies have reported it to effectively block viral protein 
expression and virion release [45]. However, activity against 
SARS-CoV-2 is currently unknown, and currently no case re-
ports on sirolimus in SOT patients with COVID-19 have been 
reported to date. Based on its track-record with encouraging 
results in other CoV diseases, sirolimus treatment might be 
an interesting option for clinical trials with COVID-19 in SOT 
Neuropsychiatric effects in SOT patients on tacrolimus 
with COVID-19 can be difficult to interpret. First of all, it can 
be due to toxic levels of tacrolimus, leading to various neuro-
toxic side effects, including tremors, headaches, dysarthria, 
neuropathies, delirium, cognitive impairment, somnolence, 
seizures and posterior reversible encephalopathy syndrome 
(PRES). Presentation as PRES can also be more subtle, such 
as described in a case report with a patient presenting with a 
bilateral optic neuropathy, but progressing further to mental 
changes and weakness of the extremities [29].
Secondly, there is also growing evidence of COVID-19 re-
lated neuropsychychiatric symptoms. These symptoms can 
be seen during the acute SARS-CoV-2 infection, but also after 
weeks, months or maybe longer in recovered patients, and 
may have been under diagnosed previously [30]. In other vi-
ral infections, such as the 2009 influenza (H1N1) pandemic 
[31], SARS (2003) [32] and MERS (2012) [33], inflammatory 
disorders of the central nervous system (CNS) have been 
described, including narcolepsy, seizures, encephalitis, en-
cephalopathy, and Guillain-Barré syndrome. A neuroinvasive 
component has been demonstrated as a common feature 
of coronaviruses [13]. It is important to bear these poten-
tial adverse outcomes in mind for the coming months as the 
pandemic evolves further. Currently insufficient data from 
COVID-19 cases is available to assess these potential sequa-
lae, also due to the limited follow-up time. On the other hand, 
in therapeutic doses, tacrolimus could have a beneficial effect 
on COVID-19 outcome, by inhibiting the pro-inflammatory cy-
tokines in the severe stage [9,34].
Cyclosporine A (CsA), the CNI of second choice in many 
transplant centers, can also lead to relevant drug-drug in-
teractions in this context. In the literature, only 2 case re-
ports described high concentrations cyclosporine during CQ 
therapy [35,36]. Any medication combination in a transplant 
recipient including CQ or HCQ, should be accompanied by 
routine pharmacokinetic monitoring due to potentially rele-
vant interactions [19]. Some authors recommend strongly a 
dose reduction and estimate that the half-life of CsA is pro-
longed 5- to 20-fold due to interaction with lopinavir/ritona-
vir, therefore dosing regimens of cyclosporin 25 mg every 1-2 
days have been suggested [21].
The dose of the antiproliferative agent mycophenolate 
mofetil (MMF) is usually intentionally reduced in COVID-19 as 
part of the treatment strategy in analogy to experience with 
other respiratory viral infections. Currently no data on import-
ant pharmacokinetic interactions concerning MMF with the 
above described treatment options for COVID-19 are known 
yet. Some authors recommend discontinuing MMF entirely 
in case of severe COVID-19 in SOT recipients [21]. This was 
based on the H1N1 pandemic, where MMF treatment result-
ed in a reduced immune response in SOT recipients [37,38]. 
If MMF treatment is continued, close monitoring of trough 
levels and MMF dosage adjustments are advised [21].
Corticosteroids concentrations are not routinely moni-
tored. The CDC recommended avoiding high-dose corticoste-
roids in patients with COVID-19, based on interference with 
virus elimination and possibly prolonged viral replication and 
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17. Wang Y, Zhang D, Du G, et al. (2020) Remdesivir in adults with 
severe COVID-19: A randomised, double-blind, placebo-con-
trolled, multicentre trial. The Lancet 395: 1569-1578. 
18. Glaus MJ, Ruden S Von (2020) Remdesivir and COVID-19. The 
Lancet 396: P952. 
19. Mahmoudjafari Z, Alexander M, Roddy J, et al. (2020) Ameri-
can society for transplantation and cellular therapy pharmacy 
special interest group position statement on pharmacy practice 
management and clinical management for COVID-19 in hemato-
poietic cell transplantation and cellular therapy patients in the 
United States. Biol Blood Marrow Transplant 26: 1043-1049.
20. Liu J, Cao R, Xu M, et al. (2020) Hydroxychloroquine, a less toxic 
derivative of chloroquine, is effective in inhibiting SARS-CoV-2 
infection in vitro. Cell Discov 6: 16. 
recipients.
Summarizing the interactions in SOT patients with 
COVID-19, tacrolimus, cyclosporine and sirolimus drug levels 
can be elevated in combination with CQ/HCQ, and also with 
lopinavir/ritonavir treatment, and are decreased in combi-
nation with tocilizumab, while probably being unchanged 
in combination with remdesivir and ribavirin. Especially the 
strong interaction of sirolimus with lopinavir/ritonavir should 
be considered. For mycophenolate mofetil, no relevant in-
teractions with these potential anti-COVID-19 drugs are to 
be expected. In many transplant centers, generally MMF is 
discontinued on initial admission and throughout the course 
of COVID-19, while tacrolimus and prednisone are continued. 
Caution and careful clinical and pharmacological monitoring 
of drug levels in SOT recipients with COVID-19 is mandatory.
Lung transplantation as consequence of COVID-19
Patients with previously healthy lungs may become lung 
transplant candidates due to the consequences of end-stage 
COVID-19 pneumonia. In one case report, two Chinese pa-
tients (66-year-old woman and a 70-year-old male) on extra-
corporeal membrane oxygenation (ECMO) after COVID-pneu-
monia, underwent a lung transplantation as the only way to 
save their lives. The long-term results are to be awaited, how-
ever, in the resected lungs of both patients, live SARS-CoV-2 
could no longer be detected anymore, possibly suggesting a 
short persistence of virus despite triggering major pathoge-
netical mechanisms [46].
Conclusion
Based on the limited research data, no firm conclusions 
can be made yet concerning the best treatment option for 
SOT recipients with COVID-19. The current evidence suggests 
that immunosuppression, especially including the calcineurin 
inhibitors, improves the outcome of SARS-CoV-2 infection 
and COVID-19, preventing or suppressing hyperinflammation 
(cytokine storm) in these patients, thus leading to less severe 
COVID-19 presentations. Pharmacological treatment options 
for COVID-19 need to take into account the risks of drug-drug 
interactions affecting the overall immunosuppression and 
toxicity. Being on immunosuppressive treatment appears to 
blunt the inflammatory reaction typically seen in immuno-
competent patients with a cytokine storm. Evidence based 
guidelines are urgently needed.
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